|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-5-28
|
|
pubmed:abstractText |
Gemcitabine is an efficacious cytotoxic agent used in the treatment of unresectable pancreatic carcinoma (PC). Recently, gemcitabine resistance has been associated with the ribonucleotide reductase subunit M2 (RRM2). In this prospective study, we hypothesized that RRM2 expression in PC biopsy specimens would be a significant predictor of outcome.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0944-1174
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
389-94
|
|
pubmed:meshHeading |
pubmed-meshheading:17530364-Adult,
pubmed-meshheading:17530364-Aged,
pubmed-meshheading:17530364-Aged, 80 and over,
pubmed-meshheading:17530364-Antimetabolites, Antineoplastic,
pubmed-meshheading:17530364-Biopsy, Fine-Needle,
pubmed-meshheading:17530364-Deoxycytidine,
pubmed-meshheading:17530364-Female,
pubmed-meshheading:17530364-Humans,
pubmed-meshheading:17530364-Male,
pubmed-meshheading:17530364-Middle Aged,
pubmed-meshheading:17530364-Pancreatic Neoplasms,
pubmed-meshheading:17530364-Prognosis,
pubmed-meshheading:17530364-Prospective Studies,
pubmed-meshheading:17530364-Protein Subunits,
pubmed-meshheading:17530364-RNA, Messenger,
pubmed-meshheading:17530364-Ribonucleoside Diphosphate Reductase,
pubmed-meshheading:17530364-Survival Analysis
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
|
|
pubmed:affiliation |
Fourth Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishishinjuku, Tokyo 160-0023, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
